Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 07 December 2016

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Proximal Crohn's disease location associated with disease behavior and surgery

This month's American Journal of Gastroenterology examines the relationship between proximal Crohn's disease location and disease behavior and surgery.

News image

In classifying Crohn's disease location, proximal disease includes esophagogastroduodenal and jejunal disease.

Dr Mark Lazarev from Maryland, USA determined the influence of proximal disease on outcomes of behavior and need for surgery.

In addition, the team determined if there was significant clinical heterogeneity between esophagogastroduodenal and jejunal disease.

The team of doctors performed a cross-sectional query of the NIDDK Inflammatory Bowel Disease Genetics Consortium database of patients with a confirmed diagnosis of Crohn's disease and phenotyped per the Inflammatory Bowel Disease Genetics Consortium  manual.

Presence of any location, proximal location, proximal-esophagogastroduodenal, L4-jejunal, and non-location, proximal disease was compared with demographic features including age, race, ethnicity, smoking and inflammatory bowel disease  family history, diagnosis age, disease duration, clinical outcomes of inflammatory, stricturing or penetrating behavior, and Crohn's disease abdominal surgeries.

Among 2,105 patients with complete disease location data, 346 had location, proximal disease with 321 having concurrent L1-L3 disease.

Stricturing risks were ileal site, longer disease duration
American Journal of Gastroenterology

In all, 1,759 had only L1-L3 disease.

The doctors noted that proximal patients were more likely to be younger at diagnosis, non-smokers, have coexisting ileal involvement, and have stricturing disease.

The team noted that proximal-esophagogastroduodenal patients were at least twice as likely to have had ileal disease, stricturing behavior, and any or multiple abdominal surgeries.

The research team noted that proximal-jejunal patients had more stricturing behavior and multiple abdominal surgeries than non-location, proximal ileal disease patients.

The researchers showed that stricturing risks were ileal site, longer disease duration, jejunal site, and older age at diagnosis.

Multiple surgery risks were disease duration, penetrating disease, and jejunal site, with short duration from diagnosis to first surgery protective.

Dr Lazarev's team commented, "Jejunal disease is a significantly greater risk factor for stricturing disease and multiple abdominal surgeries than either esophagogastroduodenal or ileal disease."

"The Montreal site classification should be revised to include separate designations for jejunal and esophagogastroduodenal disease."

Am J Gastroenterol 2013; 108:106–112
21 January 2013

Go to top of page Email this page Email this page to a colleague

 07 December 2016 
Iron deficiency in ulcerative colitis
 07 December 2016 
IBD source of information and patient education
 07 December 2016 
End-of-rotation resident transition and in-hospital mortality
 06 December 2016 
Anti-TNF therapy for IBD
 06 December 2016 
Crohn's disease and thyroid cancer risk
 06 December 2016 
IBD Disability Index in restorative proctocolectomy
 05 December 2016 
Reducing hospitalization in IBD
 05 December 2016 
Disease mangement in IBD
 05 December 2016 
New biomarkers for IBD diagnosis
 02 December 2016 
Hep E in acute liver failure
 02 December 2016 
Occurrence and severity of alcoholic hepatitis
 02 December 2016 
Food antigen in active eosinophilic esophagitis
 01 December 2016 
Iron deficiency in anemic ulcerative colitis patients
 01 December 2016 
Prognostic factors after paracetamol-induced liver failure
 01 December 2016 
Factors that influence colorectal cancer screening findings
 30 November 2016 
Certolizumab pegol in Crohn's disease
 30 November 2016 
Genetic risk of Crohn's in chronic granulomatous disease
 30 November 2016 
Rifaximin in diarrhea-predominant IBS
 29 November 2016 
Assessing liver steatosis
 29 November 2016 
Treating Zenker's diverticulum
 29 November 2016 
Colorectal cancer surveillance in ulcerative colitis
 28 November 2016 
Complications in celiac disease
 28 November 2016 
Monitoring IBD with mobile technology
 28 November 2016 
Reducing warfarin-related upper GI bleeds
 25 November 2016 
Metal vs plastic stents for pancreatic cancer surgery
 25 November 2016 
Yoga and IBS therapy 
 25 November 2016 
Colorectal cancer screening issues
 24 November 2016 
Partner burden in celiac disease
 24 November 2016 
Fusobacterium nucleatum for colorectal cancer prognosis
 24 November 2016 
PPIS and gastric cancer risk
 23 November 2016 
Quality assurance standards for colonoscopy
 23 November 2016 
Diagnosing autoimmune pancreatitis
 23 November 2016 
Readmissions in cirrhosis
 22 November 2016 
Bile acid diarrhea in function bowel disorder with diarrhea
 22 November 2016 
Fatigue in IBD
 22 November 2016 
PPIs and C. diff in ICU 
 21 November 2016 
Pain after endoscopic resection of gastric tumors
 21 November 2016 
Antivirals and chemotherapy in Hep C patients with cancer
 21 November 2016 
Financial incentives and colorectal cancer screening
 18 November 2016 
Colorectal cancer risk and self-reported family history
 18 November 2016 
Ustekinumab in Crohn’s disease
 18 November 2016 
Antivirals and chemotherapy in Hep C patients with cancer
 17 November 2016 
Liver-related specialty care in patients with Hep C
 17 November 2016 
Risk of overweight in infants
 17 November 2016 
Moderate alcohol consumption and NAFLD
 16 November 2016 
PPI therapy in liver disease
 16 November 2016 
Education in Gastroenterology fellowship
 16 November 2016 
Paternal preconceptional use of anti-TNF-α agents
 15 November 2016 
Novel treatment of NASH 
 15 November 2016 
Contraceptives and ulcerative colitis
 15 November 2016 
Physician perspectives on Hep C management
 14 November 2016 
Cardiovascular risk in NAFLD 
 14 November 2016 
Vit D and NAFLD
 14 November 2016 
Malignancy risk in IBD 
 11 November 2016 
Treatment of Hep C along with opioid agonist therapy
 11 November 2016 
Diabetes and liver cancer risk in Hep C cirrhosis
 11 November 2016 
Biomarker of cirrhosis progression
 10 November 2016 
Testosterone levels and cirrhosis outcomes in men
 10 November 2016 
Improving bowel quality before colonoscopy
 10 November 2016 
Fecal microbiota transplantation and CDI episodes

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2016 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us